Nicole Vitullo

Nicole Vitullo has served as a member of Esperion’s Board of Directors since 2008. Nicole has been a Partner of Domain Associates, LLC, since 2004. She joined Domain in 1999. In addition to investment responsibilities, Nicole is involved with the liquidation and distribution strategies for the public companies in Domain’s venture capital portfolios. For more than a decade, Nicole was responsible for Domain Public Equity Partners L.P., a fund focused on private investments in public companies.

With extensive experience in both public and private investing, Nicole’s current board memberships include Antios Therapeutics, Exalys Therapeutics, and Marinus Pharmaceuticals. Additionally, she was a former board observer at Iterum Therapeutics. Past board memberships include Achillion Pharmaceuticals (sold to Alexion), Calixa Therapeutics (sold to Cubist Pharmaceuticals), Celator Pharmaceuticals (sold to Jazz Pharmaceuticals), Cerexa (sold to Forest Laboratories), Durata Therapeutics (sold to Actavis), Onyx Pharmaceuticals, and VentiRx Pharmaceuticals (sold to Celgene). Prior to Domain, Nicole was Senior Vice President at Rothschild Asset Management, Inc., where she was responsible for the U.S. public market investments of International Biotechnology Trust plc and Biotechnology Investments Limited.